Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test
The pathological anatomy laboratory, which is managed by the IPG, would involve monitoring patients being treated for cancer and receiving care at the GHDC in order to take blood samples from those in whom the presence of plasma ctDNA carrying a mutation in a specific gene is suspected - a mutation detectable by the TST79 test.
lung adenocarcinoma [+9]